CytomX Therapeutics (CTMX) Cash from Operations (2014 - 2026)

CytomX Therapeutics has reported Cash from Operations for 13 years, with the latest figure at 25549000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations fell 21.41% year-over-year to 25549000.0; the trailing twelve-month figure through Mar 2026 stood at 80093000.0 (up 1.4% YoY), and the FY2025 full-year result was 75587000.0, up 12.34% from the prior year.
• Cash from Operations for Q1 2026 stood at 25549000.0, down from 23243000.0 in the prior quarter.
• The five-year high for Cash from Operations was 9349000.0 in Q1 2023, with the low at 41313000.0 in Q1 2022.
• Historically, Cash from Operations has averaged 20834705.88 across 5 years, with a median of 21043000.0 in 2025.
• The largest YoY upside for Cash from Operations was 122.63% in 2023 against a maximum downside of 1476.67% in 2023.
• CytomX Therapeutics' Cash from Operations stood at 1393000.0 in 2022, then tumbled by 1476.67% to 21963000.0 in 2023, then grew by 9.36% to 19908000.0 in 2024, then fell by 16.75% to 23243000.0 in 2025, then retreated by 9.92% to 25549000.0 in 2026.
• The last three Cash from Operations figures came in at 25549000.0 (Q1 2026), 23243000.0 (Q4 2025), and 15548000.0 (Q3 2025), per Business Quant data.